An Explorative Psoriasis Biomarker Study

NCT ID: NCT04394936

Last Updated: 2025-06-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-01
• Study Completion Date: 2023-03-27

Brief Summary

Plaque psoriasis may be an ideal model disease to explore potential therapeutic effects of immunosuppressive agents, given the easy accessibility of inflammatory lesions. In this study, the applicability of a systems dermatology approach is investigated in order to better assess the efficacy of psoriasis treatments at an early clinical stage. Up to this point, the clinical manifestation and regression of psoriasis is not yet sufficiently characterized with a multimodal state-of-the-art evaluation tool. The in-house developed 'DermaToolbox' enables the determination and subsequent integration of different diseaserelated biomarkers, including clinical, biophysical, molecular, cellular, and imaging markers as well as patient reported outcomes

Detailed Description

Psoriasis is a common skin disorder affecting up to an estimated 3% of the world's population. The most prevalent form of psoriasis, called psoriasis vulgaris or plaque psoriasis, is characterized by the presence of sharply demarcated erythematous plaques covered with white scales. These lesions can occur all over the body, but are most often seen on the extensor surface of the joints, nether regions and on the scalp. Patients can experience excessive itch, pain and sometimes bleeding of the lesions. Moreover, the visual appearance of psoriatic lesions can severely impact the patients psychological state and quality of life. An abundancy of different factors contributes to the pathogenesis of psoriasis. However, aberrant inflammatory reactions in the skin are thought to be the underlying cause. Excessive infiltration of immune cells in the skin and their interactions with cutaneous resident cells results in the hyper proliferation of keratinocytes and subsequent thickening of the epidermis. Indeed, more and more immunosuppressive biologicals targeting specific components of the immune system, like tumor necrosis factor alpha (TNFα), interleukin (IL-)17 and IL-23, have shown excellent efficacy in treating psoriasis Plaque psoriasis may be an ideal model disease to explore potential therapeutic effects of immunosuppressive agents, given the easy accessibility of inflammatory lesions and the good willingness of patients to participate in clinical studies. In this study, the applicability of a systems dermatology approach is investigated in order to better assess the efficacy of psoriasis treatments at an early clinical stage. Up to this point, the clinical manifestation and regression of psoriasis is not yet sufficiently characterized with a multimodal state-of-the-art evaluation tool. The in-house developed 'DermaToolbox' enables the determination and subsequent integration of different disease-related biomarkers, including clinical, biophysical, molecular, cellular, and imaging markers as well as patient-reported outcomes

Conditions

Psoriasis Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Guselkumab

Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.

Group Type: EXPERIMENTAL

Guselkumab

Intervention Type: DRUG

100 mg guselkumab administered subcutaneously

Placebo

Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.

Group Type: PLACEBO_COMPARATOR

Placebos

Intervention Type: DRUG

Sodiumchloride 0,9% solution for injection

Healthy volunteers

Healthy volunteer cohort (observational)

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Guselkumab

100 mg guselkumab administered subcutaneously

Intervention Type: DRUG

Placebos

Sodiumchloride 0,9% solution for injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or non-pregnant female subjects, 18 to 75 years of age (inclusive);

2. Healthy as defined by the absence of any uncontrolled active or uncontrolled chronic disease following a medical and surgical history, documentation of general symptoms, and a symptom-directed physical examination including vital signs;

3. Willing to give written informed consent and willing and able to comply with the study protocol; Psoriasis patients

1. Male or non-pregnant female subjects, 18 to 75 years of age (inclusive);

2. Diagnosed with plaque psoriasis at least 6 months prior to study participation

3. Willing to discontinue any psoriasis therapy other than emollients.

4. Having mild (PASI ≥1 and ≤ 5) or moderate-to-severe (PASI ≥ 10) plaque psoriasis;

Exclusion Criteria

1. History or symptoms of any uncontrolled, significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives, in the opinion of the Investigator;

2. History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that may interfere with study objectives, in the opinion of the Investigator;

3. Known infection requiring antibiotic therapy within the last three months prior to the study;

4. Immunosuppressive or immunomodulatory treatment within 30 days prior to the study;

5. Body mass index (BMI) ≤ 18.0 or ≥ 40.0 kg/m2;

6. Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year;

7. Previous participation in an investigational drug study involving the dosing of an investigational compound targeting an immune pathway within one year prior to screening;

8. Loss or donation of blood over 500 mL within three months prior to screening;

9. The use of any medication or vitamin/mineral/herbal/dietary supplement within less than 5 half-lives prior to study participation, if the Investigator judges that it may interfere with the study objectives. The use of paracetamol (up to 4 g/day) is allowed;

10. History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months of screening. Alcohol consumption will be prohibited from at least 12 hours preceding each study visit;

11. Any other condition that could interfere with the conduct of the study or the study objectives, in the opinion of the Investigator.

Psoriasis patients

1. Having primarily erythrodermic, pustular or guttate psoriasis;

2. Having medication-induced psoriasis;

3. Having previously failed on anti-IL23 therapy;

4. Having received treatments for psoriasis within the following intervals prior to the start of the study:

1. < 2 weeks for topical treatment, e.g. retinoids, corticosteroids, vitamin D analogs

2. < 4 weeks for phototherapy, e.g. PUVA, PDT

3. < 4 weeks for non-biologic systemic treatment, e.g. retinoids, methotrexate, cyclosporine, fumaric acid esters

4. < 4 weeks for etanercept

5. < 8 weeks for adalimumab

6. < 3 months for anti-IL17, anti-IL12(/23) and anti-IL23 treatments

5. History or symptoms of any significant uncontrolled disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives, in the opinion of the Investigator, excluding psoriasis and conditions that are related to psoriasis;

6. History of immunological abnormality (e.g., immune suppression, severe allergy or anaphylaxis) that may interfere with study objectives, in the opinion of the Investigator;

7. Known infection requiring antibiotic therapy within the last 3 months prior to the study, including latent tuberculosis;

8. Systemic immunosuppressive or immunomodulatory treatment within 30 days prior to the study;

9. Body mass index (BMI) ≤ 18.0 or ≥ 40.0 kg/m2;

10. Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year;

11. Loss or donation of blood over 500 mL within three months prior to screening;

12. The use of any medication or vitamin/mineral/herbal/dietary supplement within less than 5 half-lives prior to study participation, if the Investigator judges that it may interfere with the study objectives. The use of paracetamol (up to 4 g/day) is allowed;

13. History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months of screening. Alcohol consumption will be prohibited from at least 12 hours preceding each study visit;

14. Any other condition that could interfere with the conduct of the study or the study objectives, in the opinion of the Investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Centre for Human Drug Research, Netherlands

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert Rissmann, PhD

Role: PRINCIPAL_INVESTIGATOR

Centre for Human Drug Research

Locations

Centre for Human Drug Research

Leiden, , Netherlands

Countries

Netherlands

References

Rousel J, Mergen C, Bergmans ME, Bruijnincx LJ, de Kam ML, Klarenbeek NB, Niemeyer-van der Kolk T, van Doorn MBA, Bouwstra JA, Rissmann R; Next-Generation ImmunoDermatology Consortium (NGID). Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial. J Lipid Res. 2024 Aug;65(8):100591. doi: 10.1016/j.jlr.2024.100591. Epub 2024 Jul 9.

Reference Type: DERIVED

PMID: 38992724 (View on PubMed)

Other Identifiers

2019-002383-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NL70359.028.19

Identifier Type: OTHER

Identifier Source: secondary_id

CHDR1806

Identifier Type: -

Identifier Source: org_study_id